Research News From June 26, 2013
advertisement
- Teplizumab preserves C-peptide in recent-onset type 1 diabetes: 2-year results from the randomized, placebo-controlled Prot�g� trial.
- Threshold-Based Insulin-Pump Interruption for Reduction of Hypoglycemia. Free full text available in PDF format.
- HLA class II genotyping of African American type 1 diabetes patients reveals associations unique to African haplotypes.